Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Prostatectomy

Prostatectomy

Prostatectomy is a surgical procedure to remove all or part of the prostate gland, the walnut-sized male gland located below the bladder.
This operation is commonly performed to treat prostate cancer, benign prostatic hyperplasia (BPH), or other prostate-related conditions.
Prostatectomy can be done through various techniques, including open, laparascopic, and robot-assisted approaches.
The procedure aims to remove the diseased or enlarged prostate while preserving urinary and sexual function when possible.
Careful patient selection and surgical expertise are key to achieving optimal outcomes and minimizing complications after prostatectomy.

Most cited protocols related to «Prostatectomy»

1
Prognostic Value of Gleason Grading in Prostate Cancer
Cited 111 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Aftercare Biopsy Diagnosis Discrimination, Psychology Disease Progression Malignant Neoplasms Needle Biopsies Operative Surgical Procedures Optimism Pathologists Patients Prostatectomy Radiotherapy Recurrence Surgical Margins System, Genitourinary
2
EPIC-26 Prostate Cancer Outcomes Validation
Cited 100 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Brachytherapy Patient Representatives Prostate Cancer Prostatectomy Radiotherapy
3
Whole-Genome Sequencing of Prostate Tumors
Cited 90 times
The complete genomes of seven prostate tumors and patient-matched normal samples were sequenced to approximately 30-fold haploid coverage on an Illumina GA II sequencer. DNA was extracted from patient blood and from tumors following radical prostatectomy, and was subjected to extensive quality control procedures to monitor DNA structural integrity, genotype concordance, and tumor purity and ploidy. Standard paired-end libraries (~400bp inserts) were sequenced as 101bp paired-end reads. Raw sequencing data were processed by Illumina software and passed to the Picard pipeline, which produced a single BAM file for each sample storing all reads with well-calibrated quality scores together with their alignments to the reference genome. BAM files for each tumor/normal sample pair were analyzed by the Firehose pipeline to characterize the full spectrum of somatic mutations in each tumor, including base pair substitutions, short insertions and deletions, and large-scale structural rearrangements. A subset of base pair mutations and rearrangements were validated using independent technologies in order to assess the specificity of the detection algorithms. Fluorescence in situ hybridization (FISH) was also performed for selected recurrent rearrangements. The locations of all rearrangement breakpoints were compared to previously published chromatin immunoprecipitation (ChIP) binding peaks from related cell types to test for global associations between rearrangements and a range of epigenetic marks.
A complete description of the materials and methods is provided in the Supplementary Information. All Illumina sequence data have been deposited in dbGaP (http://www.ncbi.nlm.nih.gov/gap) and are available at accession phs000330.v1.p1.
Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., Onofrio R., Carter S.L., Park K., Habegger L., Ambrogio L., Fennell T., Parkin M., Saksena G., Voet D., Ramos A.H., Pugh T.J., Wilkinson J., Fisher S., Winckler W., Mahan S., Ardlie K., Baldwin J., Simons J.W., Kitabayashi N., MacDonald T.Y., Kantoff P.W., Chin L., Gabriel S.B., Gerstein M.B., Golub T.R., Meyerson M., Tewari A., Lander E.S., Getz G., Rubin M.A, & Garraway L.A. (2011). The genomic complexity of primary human prostate cancer. Nature, 470(7333), 214-220.
Publication 2010
Base Pairing BLOOD Cells Diploid Cell Fluorescent in Situ Hybridization Gene Deletion Gene Rearrangement Genome Genotype Immunoprecipitation, Chromatin Insertion Mutation Multiple Acyl Coenzyme A Dehydrogenase Deficiency Mutation Neoplasms Patients Prostatectomy Prostatic Neoplasms
4
Prostate Cancer Registry: CaPSURE Cohort
Cited 49 times
The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE™) is a national disease registry accruing men with biopsy-proven prostate adenocarcinoma, recruited from 40 urology practices, primarily community-based, across the United States. Informed consent is obtained from each patient under institutional review board supervision. Patients are treated according to their physicians’ usual practices, and are followed until time of death or withdrawal from the study. Additional details have been reported previously.13 (link), 14 (link) Eligibility for inclusion in the study was limited to men with prostate cancer diagnosed since 1992 who underwent prostatectomy as primary treatment and had at least six months of followup recorded in the registry. Those with clinically advanced disease (>cT3aN0M0) pre-operatively were ineligible, as were those had received neoadjuvant or adjuvant hormonal and/or radiation.
Detailed reporting of staging variables (ECE, SVI, SM) is variable among pathology reports accessioned to CaPSURE. In the main analysis, ECE, SVI, or SM reported as “unable to assess” were assumed to be negative; in a sensitivity analysis, cases without complete data for all variables were dropped. To examine whether cases with missing pathologic data (ECE, SVI, SM) differed from cases with complete data, we compared these groups with respect to their distributions of the original preoperative CAPRA score using a Wilcoxon rank-sum statistic. In all cases, patients with no lymphadenectomy performed were assumed to have negative LNI. Patients missing pathologic Gleason score and/or preoperative PSA were excluded.
The definition of biochemical recurrence was either 2 consecutive PSA values over 0.2 ng/ml15 (link) or any secondary treatment at least six months following surgery (treatment within six months was assumed to be adjuvant). Men not experiencing recurrence—including those dying of other causes—were censored at date of the last available PSA.
Cooperberg M.R., Hilton J.F, & Carroll P.R. (2011). The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer, 117(22), 5039-5046.
Publication 2011
Adenocarcinoma Biopsy Eligibility Determination Ethics Committees, Research Goat Hypersensitivity Lymph Node Excision Neoadjuvant Therapy Operative Surgical Procedures Patients Pharmaceutical Adjuvants Physicians Prostate Cancer Prostatectomy Prostatic Diseases Radiotherapy Recurrence Supervision
5
Immunohistochemical Evaluation of PTEN Protein
Cited 35 times
PTEN protein was visually scored using a dichotomous scoring system by two urologic pathologists (TLL and AMD). IHC scoring was blinded with respect to FISH and SNP array results, pathologic stage and final Gleason score at radical prostatectomy, as well as patient outcome. Using this system, each spot of tumor tissue was scored as negative or positive for PTEN protein by comparing staining in malignant glands with that of adjacent benign glands and/or stroma which provided an internal positive control within each tissue core. Staining was classified as negative if the intensity was markedly decreased or entirely negative across all tumor cells compared to the surrounding benign glands and/or stroma. A given spot was dropped from the analysis if these benign areas lacked PTEN staining (this occurred in <5 TMA spots total).
Lotan T.L., Gurel B., Sutcliffe S., Esopi D., Liu W., Xu J., Hicks J.L., Park B.H., Humphreys E., Partin A.W., Han M., Netto G.J., Isaacs W.B, & De Marzo A.M. (2011). PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research, 17(20), 6563-6573.
Publication 2011
Cells Exanthema Fishes Neoplasms Pathologists Patients Prostatectomy PTEN Phosphohydrolase PTEN protein, human Tissues

Most recents protocols related to «Prostatectomy»

1
Prostate Cancer Biomarker Monitoring
Not available on PMC !

Example 3

At the time of diagnosis with prostate cancer, subjects are invited to participate in a trial. A subject sample, e.g., blood, is obtained. Periodically, throughout the monitoring, watchful waiting, or active treatment of the subject, e.g., chemotherapy, radiation therapy, e.g., radiation of the prostate, surgery, e.g., surgical prostate resection, hormone therapy, a new subject sample is obtained. At the end of the study, all subject samples are tested for the level of FLNA and/or PSA, and optionally other markers. The subject samples are matched to the medical records of the subjects to correlate FLNA and/or PSA levels, as appropriate, with prostate cancer status at the time of diagnosis, rate of progression of disease, response of subjects to one or more interventions, and transitions between androgen dependent and independent status. Other markers, such as the expression level of keratin 19 and/or filamin B, the age of the subjects, or the prostate volume of the subjects, can also be analyzed in addition to filamin A and/or PSA.

US11866487B2. Filamin A binding proteins and uses thereof (2024-01-09). BPGbio, Inc. [US]. Inventors: Wenfang Sybil Wu [US], Shobha Ravipaty [US], Tracey Friss [US], Viatcheslav R. Akmaev [US], Nikunj Narendra Tanna [US].
Full text: Click here
Patent 2024
Androgens BLOOD Diagnosis Disease Progression Filamin A Filamin B Hormones Keratin-19 Operative Surgical Procedures Pharmacotherapy Prostate Prostate Cancer Prostatectomy Radiotherapy Therapeutics
2
Robotic Inguinal Hernia Repair Outcomes
This study was approved by the Institutional Review Board of the Catholic University of Korea, St. Vincent Hospital (No. VC21RASI0194). The need for informed consent was waived because of the retrospective design. The analysis used anonymous clinical data and involved no additional procedure besides routine practices in a clinical setting, presenting no risk of harming the patients.
The patients who underwent robotic inguinal hernia repair by 2 different surgeons from April 2021 to April 2022 were retrospectively analyzed. Two surgeons exhibit a difference in the experience of hernia surgeries; one with over 1,000 cases of inguinal hernia repair (surgeon A) and the other with over 100 cases of inguinal hernia repair (surgeon B). Patient data were collected and constructed from patient medical records. All operations were conducted by the 2 surgeons who had finished the robot platform training program.
Patient demographics, operation variables, and postoperative outcomes were extracted from the electronic medical record. Patient demographics include age, sex, body mass index (kg/m2), American Society of Anesthesiologists physical status classification, Charlson comorbidity index score, previous operation history, laterality of the hernia, and its size. Operation variables include the laterality of the inguinal hernia and the time from skin incision to skin closure. The mean operation time was calculated for patients who underwent surgery solely for hernia repair. Patients who received other surgical procedures, such as prostatectomy, nephrectomy, or adrenalectomy, were excluded in order to get an accurate operation time. Postoperative outcomes were assessed by a visual analog scale assessing postoperative pain, episodes of urinary difficulty, postoperative wound complications, and other postoperative 30-day morbidities.
Yoo R.N., Mun J.Y., Cho H.M, & Kye B.H. (2023). One-year experience of robotic transabdominal preperitoneal approach in a single institute: 2 different surgeons with different levels of experience. Annals of Surgical Treatment and Research, 104(3), 176-181.
Publication 2023
Adrenalectomy Anesthesiologist Ethics Committees, Research Functional Laterality Groin Hernia Hernia, Inguinal Herniorrhaphy Index, Body Mass Nephrectomy Operative Surgical Procedures Pain, Postoperative Patients Physical Examination Postoperative Complications Prostatectomy Roman Catholics Skin Surgeons Training Programs Urine Visual Analog Pain Scale Wounds
3
BPH Surgical Outcomes: Longitudinal Study
Patients who were newly diagnosed BPH between January 2007 and December 2012, and subsequently received prostate surgery were included. The ICD code for BPH was ICD-9-CM 600. The exclusion criteria included prostate cancer diagnosed before or after surgery, transurethral incision or resection within a year before surgery, history of open prostatectomy, and history of spinal cord injury. History of prostate cancer was identified by medical records, preoperative transurethral biopsy results, and biopsy retrieved peri-operatively. All patients included were followed up to December 2021 for last hospital visit or death.
Hsueh C.H., Chang L.W., Chiu K.Y., Hung S.C., Chen J.P, & Li J.R. (2023). Chronic kidney disease, preoperative use of antispasmodics and lower resected prostate volume ratios are risk factors for postoperative use of adrenergic Alpha-blockers and antispasmodics. PLOS ONE, 18(3), e0282745.
Full text: Click here
Publication 2023
Biopsy Operative Surgical Procedures Patients Prostate Prostate Cancer Prostatectomy Spinal Cord Injuries
4
Prostate Cancer Tissue Collection Protocol
A total of 36 pairs of fresh prostate cancer tissues and matched benign adjacent prostate tissues were collected from patients with prostate cancer at the Department of Urology of Shanghai Pudong Hospital affiliated with Fudan University (Shanghai, China) between May 2018 and November 2020. The protocols used in the present study were approved by the Shanghai Pudong Hospital Ethics Review Committee and written informed consent to participate was obtained from all patients prior to surgery. The specimens were classified according to the 2016 World Health Organization criteria and the TNM staging system (16 (link)). The size and Gleason score of each tumor was recorded (17 (link)). The clinicopathological features of the patients are shown in Table I. The inclusion criteria were as follows: Aged between 50–79 years; pathologically confirmed prostate cancer; accepted prostatectomy; and willing to participate in the study. The exclusion criteria were as follows: Aged <50 or >79 years; another active malignancy, with the exception of non-melanoma skin cancer, in addition to prostate cancer; did not accept prostatectomy; and unwilling to participate in the study.
Sang W., Zhu R., Liu D, & Gong M. (2023). LncRNA SPRY4‑IT1 is upregulated and promotes the proliferation of prostate cancer cells under hypoxia in vitro. Oncology Letters, 25(4), 138.
Publication 2023
Cancer of Skin Familial Atypical Mole-Malignant Melanoma Syndrome Malignant Neoplasms Melanoma Neoplasms Operative Surgical Procedures Patients Prostate Prostate Cancer Prostatectomy Tissues
5
Postoperative Urinary Leakage After Prostate Cancer Surgery
The present study protocol was reviewed and approved by the Ethics Committee of National Hospital Organization Okayama Medical Center (approval no. 2021-039). Informed consent was obtained using the opt-out method. The study procedures were conducted in accordance with the Declaration of Helsinki.
For this retrospective study, we evaluated the medical records of patients who underwent radical prostatectomy for prostate cancer treatment at our institution between November 2015 and March 2021. The surgical procedures performed were laparoscopic radical prostatectomy (LRP) and retropubic radical prostatectomy (RRP). In patients who underwent LRP or RRP, urethral catheters were removed 6 days after surgery. In cases where the patient had diabetes mellitus or the leak test during surgery showed leakage from the vesicourethral anastomosis, urethral catheters were removed only after an evaluation by cystourethrography 6 days after surgery. If the cystourethrography showed leakage, removal of the catheter was postponed. In cases where the patient showed urinary retention after catheter removal, the catheter was placed again. After catheter removal, patients themselves recorded urine volume per voiding. The leak urine volume was calculated using the volume of safety pads. We defined the ULR as the percentage of the leaked urine volume relative to the total urine volume in a 24-hour period, from 24:00 midnight on the day of catheter removal to 24:00 midnight the following day.
The following patients were excluded from the analysis: cases in which the leaked urine volume data was not recorded, those in which the urethral catheter removal was not performed as scheduled, and those who had preoperative urinary incontinence.
Watari S., Ichikawa T., Shiraishi H., Tokunaga M., Kubota R., Kusumi N, & Tsushima T. (2023). Efficacy of urine loss ratio for prognosis of urinary continence after radical prostatectomy: A retrospective cohort study in a single Japanese institution. Investigative and Clinical Urology, 64(2), 168-174.
Publication 2023
Anastomotic Leak Catheters Diabetes Mellitus Ethics Committees, Clinical Laparoscopy Operative Surgical Procedures Patients Prostate Cancer Prostatectomy Prostatectomy, Retropubic Retention (Psychology) Safety Urethral Catheters Urinary Catheter Urinary Incontinence Urine

Top products related to «Prostatectomy»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Du145 by American Type Culture Collection
Sourced in United States, United Kingdom, China, France, Germany, Sweden, Canada, Australia, Japan
The DU145 is a laboratory cell line derived from a human prostate carcinoma. It is widely used in cancer research for the study of cell biology and the development of potential therapies.
3
Manual tissue arrayer by Beecher Instruments
Sourced in United States
The Manual Tissue Arrayer is a laboratory instrument designed for the construction of tissue microarrays. It allows users to extract small core samples from donor tissue blocks and transfer them to a recipient paraffin block, creating a matrix of tissue samples for subsequent analysis.
4
Lncap by American Type Culture Collection
Sourced in United States, United Kingdom, Italy, Germany, France, China, Canada, Denmark, Switzerland, Spain, Australia
The LNCaP cell line is a human prostate adenocarcinoma cell line. It is a well-characterized in vitro model system for the study of prostate cancer.
5
Pregm media by Lonza
Sourced in Switzerland, United States
PrEGM media is a cell culture medium designed for the growth and maintenance of primary endothelial cells. It provides the necessary nutrients and growth factors required for the in vitro culture of endothelial cells.
6
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
7
Rneasy ffpe kit by Qiagen
Sourced in Germany, United States, Netherlands, United Kingdom, Japan, Canada, Spain, Italy, France, China, Sweden
The RNeasy FFPE Kit is a laboratory product designed for the purification of total RNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples. It provides a reliable method for extracting high-quality RNA from challenging FFPE samples.
8
Human exon 1.0 st microarray by Thermo Fisher Scientific
Sourced in United States
The Human Exon 1.0 ST microarray is a high-density oligonucleotide array designed to provide comprehensive coverage of known and predicted exonic sequences across the human genome. The array enables the analysis of gene expression at the exon level, allowing for the detection and quantification of alternative splicing events.
9
Rneasy mini kit by Qiagen
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
10
Trizol reagent by Thermo Fisher Scientific
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.

More about "Prostatectomy"

Prostatectomy is a surgical procedure to remove all or part of the prostate gland, the walnut-sized male reproductive organ located below the bladder.
This operation is commonly performed to treat prostate cancer, benign prostatic hyperplasia (BPH), or other prostate-related conditions.
Prostatectomy can be performed using various techniques, including open, laparoscopic, and robot-assisted approaches.
The goal of the procedure is to remove the diseased or enlarged prostate while preserving urinary and sexual function when possible.
Proper patient selection and surgical expertise are crucial to achieving optimal outcomes and minimizing complications after prostatectomy.
Prostate cancer is one of the most common types of cancer in men, and prostatectomy is a common treatment option.
The FBS, DU145, and LNCaP cell lines are commonly used in prostate cancer research to study the biology and behavior of prostate cancer cells.
The PrEGM media is often used to culture these cell lines.
Tissue microarrays, created using a manual tissue arrayer, can be used to analyze the expression of various proteins in prostate cancer samples.
In addition to cancer, prostatectomy may also be performed to treat benign prostatic hyperplasia (BPH), a condition characterized by the enlargement of the prostate gland.
The SAS 9.4 software and the RNeasy FFPE Kit can be used to analyze gene expression data from prostate tissue samples.
The Human Exon 1.0 ST microarrays and the RNeasy Mini Kit can also be used to study gene expression changes in prostate tissue.
Overall, prostatectomy is a critical procedure in the management of prostate-related conditions, and the advancements in surgical techniques and research tools have helped improve patient outcomes.
By understanding the various aspects of prostatectomy and the related research tools, clinicians and researchers can develop more effective treatments and improve the quality of life for men affected by prostate-related disorders.